文献速递呼吸衰竭与机械通气儿科与产科急症

2017-2023年儿童呼吸道合胞病毒住院情况

Pediatric Respiratory Syncytial Virus Hospitalizations, 2017-2023.
PubMed 文献 · JAMA Netw Open · 2024-06-03
一句话结论加拿大安大略省2022-2023年RSV住院率较疫情前翻倍以上(770.0/10万),ICU入住率为疫情前三倍(106.9 vs 27.6-36.6/10万)。

该基于人群的队列研究纳入加拿大安大略省2017年7月1日至2023年3月31日所有5岁以下儿童,每研究年约70万人,比较2021-2022和2022-2023两个RSV季节与疫情前(2017-2018、2018-2019、2019-2020)的RSV住院和ICU入住率及患儿特征。2021-2022季节高峰略早但总住院率与疫情前相当(289.1 vs 281.4-334.6/10万,约2000例住院);2022-2023季节高峰提前一个月,住院超过疫情前两倍(770.0/10万,n=4977例住院),ICU入住比例13.9%略高于疫情前9.6%-11.4%,但人群ICU入住率为疫情前三倍(106.9 vs 27.6-36.6/10万)。除palivizumab适用儿童外,2021-2022年所有社会人口学和健康状况特征均与低于预期的RSV住院率相关;2022-2023年较大年龄(24-59月龄)与高于预期的住院率相关(RR 1.90,95%CI 1.35-2.66)。作者认为尚不清楚非典型RSV流行是否及持续多久,临床医生和项目规划者应考虑对医疗能力和RSV免疫规划的可能持续影响。

要点

  • 2022-2023季节RSV住院率770.0/10万(n=4977例),超过疫情前(281.4-334.6/10万)两倍,高峰提前一个月。
  • 2022-2023年ICU入住比例13.9%,略高于疫情前9.6%-11.4%;人群ICU入住率106.9/10万,为疫情前27.6-36.6/10万的三倍。
  • 2021-2022季节住院率与疫情前相当(289.1 vs 281.4-334.6/10万,约2000例住院),高峰略早。
  • 2022-2023年24-59月龄儿童RSV住院率高于预期(RR 1.90,95%CI 1.35-2.66)。
  • 作者认为尚不清楚非典型RSV流行是否及持续多久,临床医生和项目规划者应考虑对医疗能力和RSV免疫规划的可能持续影响。

适用人群与场景

  • 加拿大安大略省所有5岁以下儿童,研究期间2017年7月1日至2023年3月31日,每研究年约70万人。

研究设计与关键结果

  • 研究设计:基于人群的队列研究,纳入加拿大安大略省2017年7月1日至2023年3月31日所有5岁以下儿童,每研究年约70万人;采用Poisson广义估计方程建模周年龄和性别特异住院率并估计疫情后预期率,报告调整率比(RR)和95%CI。
  • 2021-2022季节RSV高峰略早于疫情前(2017-2018、2018-2019、2019-2020),总住院率与疫情前相当(289.1 vs 281.4-334.6/10万,约2000例住院)。
  • 2022-2023季节高峰提前一个月,住院超过疫情前两倍(770.0/10万;n=4977例住院)。
  • 2022-2023年ICU入住比例13.9%,略高于疫情前9.6%-11.4%;人群ICU入住率106.9/10万,为疫情前27.6-36.6/10万的三倍。
  • 除palivizumab适用儿童外,2021-2022年所有社会人口学和健康状况特征均与低于预期的RSV住院率相关。
  • 2022-2023年较大年龄与高于预期的住院率相关:24-59月龄RR 1.90(95%CI 1.35-2.66)。

证据类型、等级与局限

  • 证据类型:基于人群的队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,尚不清楚非典型RSV流行是否及持续多久;临床医生和项目规划者应考虑对医疗能力和RSV免疫规划的可能持续影响。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Respiratory syncytial virus (RSV) transmission was disrupted worldwide following the COVID-19 pandemic, and further study is required to better understand these changes.

OBJECTIVE: To compare observed and expected RSV hospital and intensive care unit (ICU) admission rates and characteristics of admitted children during the 2021-2022 and 2022-2023 seasons.

DESIGN, SETTING, AND PARTICIPANTS: A population-based cohort study of all children aged younger than 5 years in Ontario, Canada, July 1, 2017, through March 31, 2023, was conducted.

EXPOSURES: Individual and neighborhood-level sociodemographic and clinical characteristics were identified from administrative data, including age, palivizumab eligibility, complex medical conditions, rurality, and living in a marginalized neighborhood.

MAIN OUTCOMES AND MEASURES: The main outcome was RSV-associated hospitalization. Secondary outcomes included ICU admissions, mechanical ventilation, extracorporeal membrane oxygenation, and in-hospital death. Poisson generalized estimating equations were used to model weekly age- and sex-specific hospitalization rates and estimate expected rates in the postpandemic era; adjusted rate ratios (RRs) and 95% CIs are reported.

RESULTS: This cohort study included approximately 700 000 children per study year. Compared with prepandemic years (2017-2018, 2018-2019, and 2019-2020), the 2021-2022 RSV season peaked slightly earlier, but overall admission rates were comparable (289.1 vs 281.4-334.6 per 100 000, or approximately 2000 admissions). The 2022-2023 season peaked a month earlier and resulted in more than twice as many hospitalizations (770.0 per 100 000; n = 4977 admissions). The proportion of children admitted to an ICU in 2022-2023 (13.9%) was slightly higher than prepandemic (9.6%-11.4%); however, the population-based rate was triple the prepandemic levels (106.9 vs 27.6-36.6 per 100 000 children in Ontario). With the exception of palivizumab-eligible children, all sociodemographic and health status characteristics were associated with lower-than-expected RSV hospitalization rates in 2021-2022. In contrast, older age of patients was associated with higher-than-expected rates in 2022-2023 (ie, 24-59 months: RR, 1.90; 95% CI, 1.35-2.66).

CONCLUSIONS AND RELEVANCE: There were notable differences in RSV epidemiologic characteristics in Ontario following the COVID-19 pandemic. It is not yet clear whether and how long atypical RSV epidemics may persist. Clinicians and program planners should consider the potential for ongoing impacts to health care capacity and RSV immunization programs.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Fitzpatrick T, Buchan SA, Mahant S, et al. Pediatric Respiratory Syncytial Virus Hospitalizations, 2017-2023. JAMA Netw Open. 2024. PMID: 38861259. doi:10.1001/jamanetworkopen.2024.16077

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。